GlassScriptPhysician profile
Lisa Joliat
NPI 1346239506
$2,093.54
in general payments reported to CMS, 2019-2025
27 companies · $1,041 in 2025
The $1,041 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.13 · 2020: $40.80 · 2021: $140 · 2022: $28.83 · 2023: $314 · 2024: $517 · 2025: $1,041.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,872.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,871.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $330.85 | 2020-2025 | Veozah |
| Abbvie INC. | $271.33 | 2021-2025 | |
| Pfizer INC. | $248.09 | 2020-2025 | |
| Novo Nordisk INC | $207.92 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Dexcom, INC. | $170.84 | 2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Abbott Laboratories | $148.89 | 2023 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $89.98 | 2024-2025 | Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.39 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $56.06 | 2025 | Mounjaro, Zepbound |
| Corcept Therapeutics | $52.35 | 2024-2025 | Korlym |
| Janssen Pharmaceuticals, INC | $46.33 | 2021-2022 | |
| Insulet Corporation | $42.83 | 2025 | Omnipod |
| Kyowa Kirin, INC. | $41.56 | 2025 | |
| Hologic Sales and Service, LLC | $33.33 | 2024 | Aptima, Thinprep 2000 Processor |
| Cequr Corporation | $30.29 | 2025 | Cequr Simplicity |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $30.13 | 2025 | Rezdiffra |
| Qol Medical, LLC | $26.85 | 2025 | Sucraid |
| Amneal Pharmaceuticals LLC | $24.75 | 2025 | Unithroid |
| Ethicon INC. | $24.48 | 2023 | Monarch Platform |
| Millicent US INC | $24.08 | 2025 | Intrarosa |
| Phathom Pharmaceuticals, INC. | $22.94 | 2025 | Voquezna |
| Eisai INC. | $21.09 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.50 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.58 | 2025 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $14.98 | 2025 | Rexulti |
| Abiomed | $14.74 | 2025 | |
| Merck Sharp & Dohme LLC | $14.38 | 2025 | Gardasil 9, Capvaxive |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Joliat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.